Fairmount Funds Management’s Viridian Therapeutics VRDN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$76.6M	Hold	3,914,458	–	–	5.53%	6
2025 Q4	$122M	Buy	3,914,458 +454,545	+13%	+$12.5M	9.27%	4
2025 Q3	$74.7M	Hold	3,459,913	–	–	6.72%	6
2025 Q2	$48.4M	Buy	3,459,913 +14,100	+0.4%	+$191K	6.27%	9
2025 Q1	$46.4M	Hold	3,445,813	–	–	7.21%	7
2024 Q4	$66.1M	Hold	3,445,813	–	–	6.57%	7
2024 Q3	$78.4M	Buy	3,445,813 +1,600,000	+87%	+$26.2M	6.36%	8
2024 Q2	$24M	Hold	1,845,813	–	–	2.71%	11
2024 Q1	$32.3M	Buy	1,845,813 +476,190	+35%	+$9.23M	3.52%	8
2023 Q4	$29.8M	Hold	1,369,623	–	–	3.15%	8
2023 Q3	$21M	Hold	1,369,623	–	–	2.53%	14
2023 Q2	$32.6M	Hold	1,369,623	–	–	4.59%	7
2023 Q1	$34.8M	Hold	1,369,623	–	–	5.99%	6
2022 Q4	$40M	Hold	1,369,623	–	–	6.35%	5
2022 Q3	$28.1M	Buy	1,369,623 +425,531	+45%	+$7.65M	5.18%	8
2022 Q2	$10.9M	Hold	944,092	–	–	2.5%	15
2022 Q1	$17.5M	Hold	944,092	–	–	4.13%	11
2021 Q4	$18.7M	Hold	944,092	–	–	6.15%	6
2021 Q3	$15.5M	Buy	944,092 +909,000	+2,590%	+$13.3M	5.65%	8
2021 Q2	$642K	Hold	35,092	–	–	0.26%	18
2021 Q1	$581K	Hold	35,092	–	–	0.24%	19
2020 Q4	$554K	Buy	+35,092	New	+$529K	0.2%	18